GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA), an immuno-oncology company focused on innovative treatments based on the Company's patent pending TriKE™ technology, announced today that Tim Schacker, M.D., Jeffrey S. Miller, M.D., and their colleagues at the University of Minnesota presented data during a poster session held at the 18th meeting of the Society for Natural Immunity in Luxembourg discussing their design of an HIV-TriKE™ containing an antigen binding fragment (Fab) from a broadly-neutralizing antibody targeting the HIV-Env protein.

In stark contrast to Democrats who seek to push all Americans into socialized medicine, an Executive Order signed on October 3 by President Donald Trump takes bold steps toward increasing the ability of American seniors to choose the medical care and insurance options best for them, instead of being trapped within increasingly insolvent government-run programs.

App Will Empower Breast Implant Patients by Providing a Digital Wallet with Their Implant Record and Serve as a Two-Way Doctor-Patient Communications Tool

New Study Shows Brainomix's Unique AI-Driven Software Gives Doctors Reliable Information to Treat Stroke Patients from Universally Available Imaging Systems